CG Oncology, Inc. Common stock (CGON) — Analyst outlook / Analyst consensus target is. Based on 9 analyst ratings, the consensus is bullish — 9 Buy.
The consensus price target is $79.00 (low: $70.00, high: $93.00), representing an upside of 17.4% from the current price $67.28.
Analysts estimate Earnings Per Share (EPS) of $-1.27 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.41 vs est $-1.27 (missed -10.7%). 2025: actual $-2.08 vs est $-2.18 (beat +4.4%). Analyst accuracy: 93%.
CGON Stock — 12-Month Price Forecast
$79.00
▲ +17.42% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for CG Oncology, Inc. Common stock, the average price target is $79.00, with a high forecast of $93.00, and a low forecast of $70.00.
The average price target represents a +17.42% change from the last price of $67.28.
Highest Price Target
$93.00
Average Price Target
$79.00
Lowest Price Target
$70.00
CGON Analyst Ratings
Buy
Based on 9 analysts giving stock ratings to CG Oncology, Inc. Common stock in the past 3 months
EPS Estimates — CGON
93%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.41
vs Est –$1.27
▼ 9.7% off
2025
Actual –$2.08
vs Est –$2.18
▲ 4.6% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — CGON
79%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.001B
vs Est $0.001B
▼ 12.4% off
2025
Actual $0.004B
vs Est $0.003B
▲ 30.3% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
